Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment - Results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)

Clinical Cardiology

Volumn 27, Issue 5, 2004, Pages 287-290

  Hallberg, Pär ^a   Karlsson, J ^a   Lind, L ^a,b   Michaelsson, K ^a   Kurland, L ^a   Kahan, T ^c   Malmqvist, K ^c   Ohman K P ^b,d   Nystrom F ^d   Liljedahl, U ^a   Syvanen, A C ^a   Melhus, H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Atenolol; Endothelin; Gender; Hypertension; Irbesartan; Polymorphism

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN 1; IRBESARTAN; PREPROENDOTHELIN 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SWEDEN; SYSTOLIC BLOOD PRESSURE;

EID: 2542539002     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960270510     Document Type: Article

References (29)

1. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T: A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens 1988;6(suppl):S188-191
2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867
3. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415
4. Kozak M, Izakovicova H, Krivan L, Vasku A, Sepsi M, Borivoj S, Vacha J: Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia. Med Sci Monit 2002;8:BR164-167
5. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP: Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 1996;90:37-46
6. Serneri GG, Modesti PA, Boddi M, Cecioni I, Paniccia R, Coppo M, Galanti G, Simonetti I, Vanni S, Papa L, Bandinelli B, Migliorini A, Modesti A, Maccherini M, Sani G, Toscano M: Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 1999;85:57-67
7. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993;72:526-538
8. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990;15:4934-96
9. Schiffrin EL, Deng LY, Sventek P, Day R: Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997;15:57-63
10. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Sasayama S: Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension 1994;23:288-293
11. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784-790
12. Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, Durand G, Desmonts JM, Levy BI, Henrion D: Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 2002;39:209-213
13. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, Dargie HJ, Arveiler D, Ruidavets JB, Luc G, Evans A, Cambien F: The Lys 198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999;33:1169-1174
14. Barden AE, Herbison CE, Beilin LJ, Michael CA, Walters BN, Van Bockxmeer FM: Association between the endothelin-1 gene Lys 198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 2001;19:1775-1782
15. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-1176
16. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H: The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) trial. J Hypertens 2002;20:2089-2093
17. Syvanen AC, Sajantila A, Lukka M: Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet 1993;52:46-59
18. Lamping KG, Nuno DW: Effects of 17 beta-estradiol on coronary microvascular responses to endothelin-1. Am J Physiol 1996;271:H1117-1124
19. Sudhir K, Ko E, Zellner C, Wong HE, Hutchison SJ, Chou TM, Chatterjee K: Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 1997;96:3626-3632
20. Polderman KH, Stehouwer CD, van Kamp GJ, Schalkwijk CG, Gooren LJ: Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000;49:648-650
21. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ: Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993;118:4294-32
22. Best PJ, Berger PB, Miller VM, Lerman A: The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998;128:285-288
23. Wang X, Barber DA, Lewis DA, McGregor CG, Sieck GC, Fitzpatrick LA, Miller VM: Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. Am J Physiol 1997;273:H1962-1967
24. Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L: Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995;80:3384-3387
25. David FL, Carvalho MH, Cobra AL, Nigro D, Fortes ZB, Reboucas NA, Tostes RC: Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001;38:692-696
26. Ergul A, Shoemaker K, Puett D, Tackett RL: Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 1998;285:511-517
27. Kellogg DL Jr, Liu Y, Pergola PE: Selected contribution: Gender differences in the endothelin-B receptor contribution to basal cutaneous vascular tone in humans. J Appl Physiol 2001;91:2407-2411; discussion 2389-2390
28. Tatchum-Talom R, Martel C, Labrie C, Labrie F, Marette A: Gender differences in hemodynamic responses to endothelin-1. J Cardiovasc Pharmacol 2000;36:S102-104
29. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Hagg A, Lind L: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-1787